Cargando…

Role of IL-16 in CD4(+) T cell-mediated regulation of relapsing multiple sclerosis

In an important article published in Nature Medicine, Liu and colleagues described a novel CD4(+) FoxA1(+) regulatory T (Treg) cell population as distinct regulators of relapsing-remitting multiple sclerosis (RRMS) and experimental autoimmune encephalomyelitis (EAE). CD4(+) FoxA1(+) Treg cells appea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skundric, Dusanka S, Cruikshank, William W, Drulovic, Jelena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426180/ https://www.ncbi.nlm.nih.gov/pubmed/25896927 http://dx.doi.org/10.1186/s12974-015-0292-x

Ejemplares similares

Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions
por: Skundric, Dusanka S, et al.
Publicado: (2006)

Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis
por: Skundric, Dusanka S.
Publicado: (2015)

Autoimmune-induced preferential depletion of myelin-associated glycoprotein (MAG) is genetically regulated in relapsing EAE (B6 × SJL) F1 mice
por: Skundric, Dusanka S, et al.
Publicado: (2008)

Multidisciplinary rehabilitation and steroids in the management of multiple sclerosis relapses: a randomized controlled trial
por: Nedeljkovic, Una, et al.
Publicado: (2015)

Multiple Choices: Regulation of Memory CD8 T Cell Generation and Homeostasis by Interleukin (IL)-7 and IL-15
por: Prlic, Martin, et al.
Publicado: (2002)

IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis
por: Stampanoni Bassi, Mario, et al.
Publicado: (2020)

Role of Neuropoietic Cytokines in Development and Progression of Diabetic Polyneuropathy: From Glucose Metabolism to Neurodegeneration
por: Skundric, Dusanka S., et al.
Publicado: (2003)

Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
por: Giordano, Andrea, et al.
Publicado: (2018)

Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
por: Craner, Matthew, et al.
Publicado: (2022)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing–Remitting Multiple Sclerosis Patients
por: Bertolotto, Antonio, et al.
Publicado: (2020)

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
por: Heming, Michael, et al.
Publicado: (2023)

IL-22, GM-CSF and IL-17 in peripheral CD4(+) T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy
por: Muls, Nathalie, et al.
Publicado: (2017)

Redox Imbalance in CD4+ T Cells of Relapsing-Remitting Multiple Sclerosis Patients
por: Tavassolifar, Mohammad Javad, et al.
Publicado: (2020)

Age at Disease Onset Associates With Oxidative Stress, Neuroinflammation, and Impaired Synaptic Plasticity in Relapsing-Remitting Multiple Sclerosis
por: Stampanoni Bassi, Mario, et al.
Publicado: (2021)

Myelin-Specific Cd8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis
por: Steinman, Lawrence
Publicado: (2001)

Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
por: Habek, Mario, et al.
Publicado: (2022)

IL-12-mediated transcriptional regulation of matrix metalloproteinases
por: Roupakia, Eugenia, et al.
Publicado: (2018)

Perforin Expression by CD4+ Regulatory T Cells Increases at Multiple Sclerosis Relapse: Sex Differences
por: Tejera-Alhambra, Marta, et al.
Publicado: (2012)

The IL‐27/IL‐27R axis is altered in CD4(+) and CD8(+) T lymphocytes from multiple sclerosis patients
por: Clénet, Marie‐Laure, et al.
Publicado: (2021)

The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells
por: Berge, T, et al.
Publicado: (2016)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) - Development of an Outcome Instrument for Educational Interventions
por: Heesen, C., et al.
Publicado: (2015)

Upregulation of CD4+T-Cell Derived MiR-223 in The Relapsing Phase of Multiple Sclerosis Patients
por: Hosseini, Aref, et al.
Publicado: (2016)

Validation of the Serbian Version of Multiple Sclerosis Spasticity Scale 88 (MSSS-88)
por: Rodic, Sindi Z., et al.
Publicado: (2016)

Multiple Sclerosis patients carry an increased burden of exceedingly rare genetic variants in the inflammasome regulatory genes
por: Vidmar, Lovro, et al.
Publicado: (2019)

In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod
por: Cavalli, Eugenio, et al.
Publicado: (2019)

Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients
por: Álvarez-Sánchez, Nuria, et al.
Publicado: (2019)

IL-21 and IRF4: A Complex Partnership in Immune and Metabolic Regulation
por: Knudsen, Nelson H., et al.
Publicado: (2014)

Identification of CD4(+) T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment
por: Fagone, Paolo, et al.
Publicado: (2019)

AZD-1222/elasomeran/tozinameran: Multiple sclerosis (MS) and relapse of MS: 16 case reports
Publicado: (2022)

IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis
por: Petržalka, Marko, et al.
Publicado: (2022)

Acetylcholine-producing CD4 T cells regulate vasculature in humans
por: Cox, Maureen A.
Publicado: (2023)

VALIDATION OF THE BRIEF INTERNATIONAL COGNITIVE ASSESSMENT FOR MULTIPLE SCLEROSIS (BICAMS) IN A LARGE COHORT OF RELAPSING-REMITTING MS PATIENTS
por: Drulović, Jelena, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021)

Luteolin as a therapeutic option for multiple sclerosis
por: Theoharides, Theoharis C
Publicado: (2009)

The Extracellular Matrix and Remyelination Strategies in Multiple Sclerosis
por: You, Yuyi, et al.
Publicado: (2018)

An insight about genomic susceptibility & multiple sclerosis
por: Verma, Rajesh, et al.
Publicado: (2017)

European and American Guidelines for Multiple Sclerosis Treatment
por: Ghezzi, Angelo
Publicado: (2018)

Chewing the fat on an emerging target in multiple sclerosis
por: Lim, Chai K.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ccgguhjqjumrutpdl25j6d2q3